Background To evaluate treatment satisfaction in the patients with chronic rheumatic diseases.
Methods This cross-sectional study was performed from September 2021 through December 2021 using treatment satisfaction questionnaire for medication (TSQM).
Results Two hundred fifteen patients (RA patients n=114, SLE patients n=101) were enrolled in this study. 82.3% were female (73.7% of RA, 92.1% of SLE, p < 0.001). The mean of age was 52.8 years (57.8 years vs. 47.2 years, p < 0.001), of disease duration was 9.1 years (6.8 years vs. 11.8 years, p < 0.001), of duration of education was 11.5 years (11.0 years vs. 12.0, p=0.010). Mean of DAS28-ESR was 2.0, of DAS28-CRP was 1.8, of SLEDAI was 1.8, and of EQ5D- VAS was 68.6. Mean of TSQM summary scores; 1) treatment effectiveness 64.5 (66.5 vs. 62.3, p=0.028), side effects 97.6 (97.9 vs. 97.3, p=0.726), convenience of administration 67.7 (66.9 vs. 68.7, p=0.268), and global satisfaction 65.2 (66.2 vs. 63.9, p=0.307). There were good correlations between TSQM and demographic data in age at symptom onset, duration of education, global assessment of patient or physician, ESR, CRP, DAS28-ESR/CRP, and SLEDAI. The score 80 or more of global satisfaction was defined as ‘satisfied’. 80 or more group (n=36, 16.7%) showed longer duration of education, higher income, lower global assessment of patients or physician, and higher EQ5D-VAS (all, p< 0.05) compared to 80 or less group. However, SLE patients with 80 or more score showed just a trend in the household income per month (p=0.054). Among EQ-5D questionnaires, the level of pain/discomfort and anxiety/depression were significantly difference between 80 or more and less group.
Conclusions Factors associated with global satisfaction ‘satisfied’ were duration of education, household income per month, pain/discomfort, or anxiety/depression in this study. Although most of them were stable disease status, patients with SLE showed lower treatment satisfaction than RA patients.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.